<div class="chapter"><div class="chapter"><h2 class="title">CHAPTER 26. <a name="page504"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">504</span></span>Blindness and its Prevention</h2><div class="section" id="ch26lev1sec1"><h1 class="title">BLINDNESS</h1>
<p class="noindent"><span class="italic">“Too blind to perform work for which eyesight is essential.”</span>  <span class="italic">—Parsons.</span></p>
<p class="noindent">The term <span class="italic">blindness</span> means inability to perceive light. There are at least 65 definitions of blindness throughout the world and they differ widely.</p>
<div class="section" id="ch26lev2sec1"><h2 class="title">Uniform Definition of Blindness (WHO)</h2>
<p class="noindent">“Visual acuity in the better eye is less than 3/60 (Snellen's) or its equivalent” or in the absence of visual acuity chart-“inability to count fingers in daylight at a distance of 3 meters” (to indicate less than 3/60 or its equivalent).</p>
</div>
<div class="section" id="ch26lev2sec2"><h2 class="title">Categories Visual Impairment and Blindness (WHO)</h2>
<p class="noindent">In 2018, WHO and the International Classification of Diseases (ICD-11) classifies vision impairment into two groups, distance and near presenting vision impairment <bold>(<a href="#ch26tbl1" class="ulink-inter">Table 26.1</a>)</bold>.</p>
</div>
<div class="section" id="ch26lev2sec3"><h2 class="title">Definition of Blindness (National Programme for Control of Blindness)</h2>
<p class="noindent">The definition of blindness under NPCB is modified in line with ‘WHO definition’: “Presenting distance visually acuity less than 3/60 (20/400) in the better eye and/or limitation of field of vision to be less than 10 degrees from center of fixation”.</p>
<p class="noindent">(Previously it was 6/60 and/or &lt;20 degrees visual field).</p>
</div>
<div class="section" id="ch26lev2sec4"><h2 class="title">Few More Definitions</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Legal blindness:</span> Visual acuity in the better eye is less than 3/60, and/or, visual field constricted to less than 10° (in India).</p></li>
<li><p class=""><span class="italic">Economical blindness:</span> Visual acuity in the better eye is less than 6/60, and/or, visual field constricted to less than 20° (in India).</p></li>
<li><p class=""><span class="italic">Visually handicapped:</span> Visual acuity in the better eye is less than 6/18 (in India).</p></li>
<li><p class=""><span class="italic">Avoidable blindness:</span> This includes both preventable blindness and curable blindness.</p>
<p class=""><div class="table" id="ch26tbl1"><div class="title"><span class="item-label">TABLE 26.1</span> Classification of severity of vision impairment based on visual acuity of the better eye (World Health Organization).</div><div class="table-scroll"><table data-label="TABLE 26.1">



<thead>
<tr>
<th class="left"><p class=""><span class="italic">Category</span></p></th>
<th colspan="2" class="left"><p class=""><span class="italic">Visual acuity of the better eye</span></p></th>
</tr>
</thead>
<tbody>
<tr>
<td class="left"><p class=""><bold>Distant vision impairment</bold></p></td>
<td class="left"><p class="">Worse than:</p></td>
<td class="left"><p class="">Equal to or better than:</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Mild vision impairment</p></li>
</ul></p></td>
<td class="left"><p class="">6/12</p></td>
<td class="left"><p class="">6/18</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Moderate vision impairment</p></li>
</ul></p></td>
<td class="left"><p class="">6/18</p></td>
<td class="left"><p class="">6/60</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Severe vision impairment</p></li>
</ul></p></td>
<td class="left"><p class="">6/60</p></td>
<td class="left"><p class="">3/60</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Blindness</p></li>
</ul></p></td>
<td class="left"><p class="">3/60</p></td>
<td class="left"></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Near vision impairment</bold></p></td>
<td class="left"><p class="">N6 or M 0.8 at 40 cm</p></td>
<td class="left"></td>
</tr>
<tr>
<td colspan="3" class="left"><p class="">Severe visual impairment and blindness are also categorized <span class="italic">according to the degree of central visual field constriction</span> in the better eye to &lt;20 degrees or &lt;10 degree respectively</p></td>
</tr>
</tbody>
</table></div><div class="additional-markup"></div></div></p>
<p class=""><a name="page505"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">505</span></span></p>
<p class=""><div class="table" id="ch26tbl2"><div class="title"><span class="item-label">TABLE 26.2</span> Visual impairment disability categories based on its severity and proposed disability percentages (Government of India).</div><div class="table-scroll"><table data-label="TABLE 26.2">




<thead>
<tr>
<th colspan="4" class="center"><p class=""><span class="italic">All with best corrections</span></p></th>
</tr>
<tr>
<th class="left"><p class=""><span class="italic">Categories</span></p></th>
<th class="left"><p class=""><span class="italic">Better eye</span></p></th>
<th class="left"><p class=""><span class="italic">Worse eye</span></p></th>
<th class="left"><p class=""><span class="italic">Percentage impairment</span></p></th>
</tr>
</thead>
<tbody>
<tr>
<td class="left"><p class="">Category 0</p></td>
<td class="left"><p class="">6/9–6/18</p></td>
<td class="left"><p class="">6/24 to 6/36</p></td>
<td class="left"><p class="">20%</p></td>
</tr>
<tr>
<td class="left"><p class="">Category I</p></td>
<td class="left"><p class="">6/18–6/36</p></td>
<td class="left"><p class="">6/60 to no PL</p></td>
<td class="left"><p class="">40%</p></td>
</tr>
<tr>
<td class="left"><p class="">Category II</p></td>
<td class="left"><p class="">6/60–4/60</p>
<p class="">or</p>
<p class="">Field of vision 10–20°</p></td>
<td class="left"><p class="">3/60 to no PL</p></td>
<td class="left"><p class="">75%</p></td>
</tr>
<tr>
<td class="left"><p class="">Category III</p></td>
<td class="left"><p class="">3/60 to 1/60 or</p>
<p class="">Field of vision &lt;10°</p></td>
<td class="left"><p class="">FC at 1 feet to no PL</p></td>
<td class="left"><p class="">100%</p></td>
</tr>
<tr>
<td class="left"><p class="">Category IV</p></td>
<td class="left"><p class="">FC at 1 feet to no PL or</p>
<p class="">Field of vision less than 10°</p></td>
<td class="left"><p class="">FC at 1 feet to no PL or</p>
<p class="">Field of vision less than 10°</p></td>
<td class="left"><p class="">100%</p></td>
</tr>
<tr>
<td class="left"><p class="">One-eyed person</p></td>
<td class="left"><p class="">6/6</p></td>
<td class="left"><p class="">FC at 1 feet to no PL</p></td>
<td class="left"><p class="">30%</p></td>
</tr>
<tr>
<td colspan="4" class="left"><p class=""><bold>Category I to IV</bold> = Visually handicapped (challenged)</p></td>
</tr>
<tr>
<td colspan="4" class="left"><p class="small"><bold>(PL—</bold>Perception of light; <bold>FC—</bold>Finger counting)</p></td>
</tr>
</tbody>
</table></div><div class="additional-markup"></div></div></p>
<p class="">85% of the blindness is estimated to be avoidable.</p></li>
<li><p class=""><span class="italic">Preventable blindness:</span> The blindness which can be easily prevented by attacking the causative factors, e.g., corneal blindness (vitamin A deficiency, trachoma, infectious keratitis, etc.), industrial blindness (by improving occupational safety conditions), retinopathy of prematurity (ROP), diabetic retinopathy, etc.</p></li>
<li><p class=""><span class="italic">Curable blindness:</span> It is almost synonymous with cataract blindness. Others are glaucoma, inflammation of ocular tissues, etc.</p></li>
</ul>
<p class="indent">In the World, 82% of people, 50 years and older are with visual impairment. Visual impairment disability categories in India are given in <bold><a href="#ch26tbl2" class="ulink-inter">Table 26.2</a></bold> and accordingly visually handicapped certificate is issued by the government. The major causes of visual impairment are uncorrected refractive errors (43%) and cataract (33%); the first cause of blindness is cataract (51%) <bold>(<a href="#ch26tbl3" class="ulink-inter">Table 26.3</a> and <a href="#ch26fig1" class="ulink-inter">Figs. 26.1A</a> and <a href="#ch26fig1B" class="ulink-inter">1B</a>)</bold>.</p>
<div class="table" id="ch26tbl3"><div class="title"><span class="item-label">TABLE 26.3</span> Causes of blindness in World and India.</div><div class="table-scroll"><table data-label="TABLE 26.3">



<thead>
<tr>
<th class="left"><p class=""><span class="italic">Causes</span></p></th>
<th class="left"><p class=""><span class="italic">India</span></p>
<p class=""><span class="italic">Vn &lt;3/60</span></p></th>
<th class="left"><p class=""><span class="italic">World</span></p>
<p class=""><span class="italic">Vn &lt;3/60</span></p></th>
</tr>
</thead>
<tbody>
<tr>
<td class="left"><p class="">Cataract</p></td>
<td class="left"><p class="">66.2%</p></td>
<td class="left"><p class="">30.3%</p></td>
</tr>
<tr>
<td class="left"><p class="">Corneal opacity</p></td>
<td class="left"><p class="">7.4%</p></td>
<td class="left"><p class="">5.1%</p></td>
</tr>
<tr>
<td class="left"><p class="">Cataract surgery complications</p></td>
<td class="left"><p class="">7.2%</p></td>
<td class="left"><p class="">*</p></td>
</tr>
<tr>
<td class="left"><p class="">Other post segment diseases</p></td>
<td class="left"><p class="">5.9%</p></td>
<td class="left"><p class="">*</p></td>
</tr>
<tr>
<td class="left"><p class="">Glaucoma</p></td>
<td class="left"><p class="">5.5%</p></td>
<td class="left"><p class="">8.0%</p></td>
</tr>
<tr>
<td class="left"><p class="">Phthisis bulbi</p></td>
<td class="left"><p class="">2.8%</p></td>
<td class="left"><p class="">*</p></td>
</tr>
<tr>
<td class="left"><p class="">Aphakia uncorrected</p></td>
<td class="left"><p class="">1.7%</p></td>
<td class="left"><p class="">*</p></td>
</tr>
<tr>
<td class="left"><p class="">Diabetic retinopathy</p></td>
<td class="left"><p class="">1.2%</p></td>
<td class="left"><p class="">4.8%</p></td>
</tr>
<tr>
<td class="left"><p class="">Trachomatous opacity</p></td>
<td class="left"><p class="">0.8%</p></td>
<td class="left"><p class="">3.8%</p></td>
</tr>
<tr>
<td class="left"><p class="">AMD</p></td>
<td class="left"><p class="">0.7%</p></td>
<td class="left"><p class="">8.2%</p></td>
</tr>
<tr>
<td class="left"><p class="">Other globe and CNS anomalies</p></td>
<td class="left"><p class="">0.5%</p></td>
<td class="left"><p class="">*</p></td>
</tr>
<tr>
<td class="left"><p class="">Refractive errors</p></td>
<td class="left"><p class="">0.1%</p></td>
<td class="left"><p class="">18.0%</p></td>
</tr>
<tr>
<td class="left"><p class="">Childhood blindness</p></td>
<td class="left"><p class="">*</p></td>
<td class="left"><p class="">3.9%</p></td>
</tr>
<tr>
<td class="left"><p class="">Onchocerciasis</p></td>
<td class="left"><p class="">*</p></td>
<td class="left"><p class="">0.9%</p></td>
</tr>
<tr>
<td class="left"><p class="">Others</p></td>
<td class="left"><p class="">*</p></td>
<td class="left"><p class="">17%</p></td>
</tr>
<tr>
<td colspan="3" class="left"><p class="small"><bold>Vn</bold>—Vision; <bold>AMD</bold>—Age-related macular degeneration; <bold>Post</bold>—Posterior; <bold>CNS</bold>—Central nervous system</p>
<p class="">*— data not available</p></td>
</tr>
</tbody>
</table></div><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch26lev2sec5"><h2 class="title">Low Vision</h2>
<p class="noindent">Visual impairment disability categories based on its severity and proposed disability.</p>
<p class="noindent"><bold>Person with low vision means:</bold> A person with visual impairment of &lt;6/18 to 3/60 with best correction in the better eye or impairment of central visual field in any of the following:</p>
<ul style="list-style-type: bullet">
<li><p class="">Reduction of fields &lt;20°<a name="page506"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">506</span></span></p>
<p class=""><div class="figure" id="ch26fig1" data-label="Fig. 26.1A"><div class="title"><span class="item-label">Fig. 26.1A</span> Causes of blindness in World and India.</div><img alt="Fig. 26.1A" src="/MediumImage/506-1.jpg"><div class="additional-markup"></div></div></p></li>
<li><p class="">Bilateral hemianopia with macular involvement</p></li>
<li><p class="">Altitudinal defect involving lower halves of visual field</p></li>
</ul>
</div>
<div class="section" id="ch26lev2sec6"><h2 class="title">Prevalence of Blindness in India (<a href="#ch26tbl4" class="ulink-inter">Table 26.4</a>)</h2>
<p class="noindent">Prevalence of visual impairment and blindness in different age-group statistical data have been described in <bold><a href="#ch26tbl5" class="ulink-inter">Tables 26.5</a> and <a href="#ch26tbl6" class="ulink-inter">26.6</a></bold>.</p>
<div class="table" id="ch26tbl4"><div class="title"><span class="item-label">TABLE 26.4</span> Prevalence of blindness in India.</div><div class="table-scroll"><table data-label="TABLE 26.4">



<thead>
<tr>
<th class="left"><p class=""><span class="italic">Year</span></p></th>
<th colspan="2" class="left"><p class=""><span class="italic">Vision in better eye</span></p></th>
</tr>
<tr>
<th class="left"></th>
<th class="left"><p class=""><span class="italic">&lt;6/60</span></p></th>
<th class="left"><p class=""><span class="italic">&lt;3/60</span></p></th>
</tr>
</thead>
<tbody>
<tr>
<td class="left"><p class="">1986–89 NPCB/WHO</p></td>
<td class="left"><p class="">1.49%</p></td>
<td class="left"><p class="">—</p></td>
</tr>
<tr>
<td class="left"><p class="">2001–04 NPCB</p></td>
<td class="left"><p class="">1.10%</p></td>
<td class="left"><p class="">—</p></td>
</tr>
<tr>
<td class="left"><p class="">2007 RAAB/NPCB</p></td>
<td class="left"><p class="">1.0%</p></td>
<td class="left"><p class="">0.62%</p></td>
</tr>
<tr>
<td class="left"><p class="">2015–19 (RAAB/NPCB VI)</p></td>
<td class="left"><p class="">—</p></td>
<td class="left"><p class="">0.36%</p></td>
</tr>
<tr>
<td colspan="3" class="left"><p class=""><bold>WHO</bold>—World Health Organization</p>
<p class=""><bold>RAAB</bold>—Rapid Assessment of Avoidable Blindness</p>
<p class=""><bold>NPCB VI</bold>—National Programme for the Control of Blindness and Visual Impairment</p></td>
</tr>
</tbody>
</table></div><div class="additional-markup"></div></div>
<p class=""><a name="page507"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">507</span></span></p>
<div class="figure" id="ch26fig1B" data-label="Fig. 26.1B"><div class="title"><span class="item-label">Fig. 26.1B</span> Causes of blindness (PVA &lt;3/60 in better eye) in 2019 in population aged ≥50 years.</div><img alt="Fig. 26.1B" src="/MediumImage/507-1.jpg"><div class="additional-markup"></div></div>
<div class="table" id="ch26tbl5"><div class="title"><span class="item-label">TABLE 26.5</span> Prevalence of blindness and low vision in World and India (WHO/NPCB VI) in 2020.</div><div class="table-scroll"><table data-label="TABLE 26.5">




<thead>
<tr>
<th class="left"></th>
<th class="left"><p class=""><span class="italic">Blindness</span></p>
<p class=""><span class="italic">BCVA &lt;3/60 in better eye</span></p></th>
<th class="left"><p class=""><span class="italic">Low vision</span></p>
<p class=""><span class="italic">(BCVA &lt;6/18 in better eye)</span></p></th>
<th class="left"><p class=""><span class="italic">Total</span></p>
<p class=""><span class="italic">visual impairment</span></p></th>
</tr>
</thead>
<tbody>
<tr>
<td class="left"><p class=""><span class="italic">World</span></p></td>
<td class="left"><p class=""><span class="italic">43 million</span></p></td>
<td class="left"><p class=""><span class="italic">295 million</span></p></td>
<td class="left"><p class=""><span class="italic">338 million</span></p></td>
</tr>
<tr>
<td class="left"><p class=""><span class="italic">India</span></p></td>
<td class="left"><p class=""><span class="italic">4.95 million</span></p></td>
<td class="left"><p class=""><span class="italic">70 million</span></p></td>
<td class="left"><p class=""><span class="italic">74.95 million</span></p></td>
</tr>
<tr>
<td colspan="4" class="left"><p class="small"><bold>Near vision problems:</bold> World – 510 million; India – 137.6 million</p></td>
</tr>
</tbody>
</table></div><div class="additional-markup"></div></div>
<div class="table" id="ch26tbl6"><div class="title"><span class="item-label">TABLE 26.6</span> Blindness in different age groups.</div><div class="table-scroll"><table data-label="TABLE 26.6" class="download">


<thead>
<tr>
<th class="left"><p class=""><span class="italic">Age-groups</span></p></th>
<th class="left"><p class=""><span class="italic">Causes of blindness</span></p></th>
</tr>
</thead>
<tbody>
<tr>
<td class="left"><p class="">Infants and preschool age</p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Congenital cataract</p></li>
<li><p class="">Congenital glaucoma</p></li>
<li><p class="">Optic atrophy</p></li>
<li><p class="">Xerophthalmia</p></li>
<li><p class="">Rare congenital</p></li>
<li><p class="">Anomalies</p></li>
<li><p class="">Trauma</p></li>
<li><p class="">Retinoblastoma</p></li>
<li><p class="">ROP</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class="">School-age</p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Congenital/developmental anomalies</p></li>
<li><p class="">Neurological (optic neuritis, papilledema)</p></li>
<li><p class="">Trauma</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class="">Adult life (20–50 years)</p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Pathological myopia</p></li>
<li><p class="">Neurological diseases</p></li>
<li><p class="">Industrial injuries</p></li>
<li><p class="">Diabetes</p></li>
<li><p class="">Infectious diseases</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class="">Late adult life (51–70 years)</p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Cataract</p></li>
<li><p class="">Glaucoma</p></li>
<li><p class="">Diabetes</p></li>
<li><p class="">Retinal vasculopathies</p></li>
<li><p class="">Cataract surgery related complications</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class="">Elderly life (above 70 years)</p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Cataract</p></li>
<li><p class="">Glaucoma</p></li>
<li><p class="">Age-related macular degeneration</p></li>
<li><p class="">Diabetes</p></li>
<li><p class="">Retinal vasculopathies</p></li>
<li><p class="">Cataract surgery related complications</p></li>
</ul></p></td>
</tr>
</tbody>
</table></div><div class="additional-markup"></div></div>
<p class=""><a name="page508"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">508</span></span></p>
</div>
</div><div class="section" id="ch26lev1sec2"><h1 class="title">NATIONAL PROGRAMME FOR THE CONTROL OF BLINDNESS</h1>
<p class="noindent">One of the basic human rights is the right to see. We have to ensure that no citizen goes blind needlessly, or being blind does not remain so, if, by reasonable deployment of skill and resources, his sight can be prevented from deteriorating, or if already lost, can be restored.</p>
<p class="alignright"><span class="italic">—National policy pronounced in 1975</span></p>
<div class="section" id="ch26lev2sec7"><h2 class="title">Overall Objectives of NPCB (1976)</h2>
<ul style="list-style-type: bullet">
<li><p class="">Provision of comprehensive eye care facilities for <span class="italic">primary, secondary, and tertiary levels</span> of eye-health care.</p></li>
<li><p class="">Substantial reduction in the prevalence of eye diseases in general and <span class="italic">reduction in the prevalence of blindness from 1.40% to 0.3% by 2000 AD.</span></p></li>
<li><p class="">National Programme for the Control of Blindness (NPCB) was launched by the Government of India, Ministry of Health and Family Welfare in the year 1976 and is a 100% centrally sponsored program with the goal of reducing the prevalence of blindness.</p></li>
<li><p class="">To reduce the backlog of blindness through identification of treatment of blind and visually impaired.
<ul style="list-style-type: square">
<li><p class="">To develop eye care facilities in every district.</p></li>
<li><p class="">To develop human resources for providing eye care services.</p></li>
<li><p class="">To improve the quality of service delivery.</p></li>
<li><p class="">To secure participation of voluntary organization in eye care.</p></li>
<li><p class="">To enhance community awareness of eye care.</p></li>
</ul></p></li>
</ul>
<p class="indent">In 2017, <span class="italic">National Programme for the Control of Blindness (NPCB) was changed to National Programme for the Control of Blindness and Visual Impairment (NPCBVI)</span>.</p>
<p class="indent"><span class="italic">Best practices adopted under this new program:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">To reach every part of the country to provide eye care services, provision for setting up Multipurpose District Mobile Ophthalmic Units in the District Hospitals of States/UTs as a new initiative under the program.</p></li>
<li><p class="">Provision for distribution of free spectacles to old persons suffering from presbyopia as a new initiative under the program.</p></li>
<li><p class="">Emphasis on the comprehensive eye care coverage by covering diseases other than cataract like diabetic retinopathy, glaucoma, corneal transplantation, vitreoretinal surgery, treatment of childhood blindness including retinopathy of prematurity (ROP), etc.</p></li>
<li><p class="">Strengthening of tertiary eye care centers by providing funds for purchase of sophisticated modern ophthalmic equipment.</p></li>
<li><p class="">Ensure setting up of superspecialty clinics for all major eye diseases including diabetic retinopathy, glaucoma, retinopathy of prematurity, etc. in state level hospitals and medical colleges all over the country.</p></li>
<li><p class="">Linkage of teleophthalmology centers at PHC/Vision centers with superspecialty eye hospitals to ensure delivery of best possible diagnosis and treatment for eye diseases, especially in hilly terrains and difficult areas.</p></li>
<li><p class="">Development of a network of eye banks and eye donation centers linked with medical colleges and RIOs to promote collection and timely utilization of donated eyes in a transparent manner.</p></li>
</ul>
</div>
<div class="section" id="ch26lev2sec8"><h2 class="title">Current Infrastructure (2020–2021)</h2>
<div class="informaltable"><div class="table-scroll"><table class="download">


<tbody>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Apex Institute</p></li>
</ul></p></td>
<td class="left"><p class="">1</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">All India Institute of Medical Sciences</p></li>
</ul></p></td>
<td class="left"><p class="">19</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Regional Institute of Ophthalmology</p></li>
</ul></p></td>
<td class="left"><p class="">20</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Upgraded Medical College</p></li>
</ul></p></td>
<td class="left"><p class="">150</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">District Hospitals equipped</p></li>
</ul></p></td>
<td class="left"><p class="">550</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">District Blindness Control Society (DBCS)</p></li>
</ul></p></td>
<td class="left"><p class="">575</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Central Mobile Ophthalmic Units</p></li>
</ul></p></td>
<td class="left"><p class="">155</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">District Mobile Ophthalmic Units</p></li>
</ul></p></td>
<td class="left"><p class="">250</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Ophthalmic Assistant Training Centers</p></li>
</ul></p></td>
<td class="left"><p class="">164</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Vision Center in Primary Health Centers</p></li>
</ul></p></td>
<td class="left"><p class="">5,000</p></td>
</tr>
<tr>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Eye Bank and Eye Donation Centers</p></li>
</ul></p></td>
<td class="left"><p class="">650</p></td>
</tr>
</tbody>
</table></div></div>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Ophthalmologists:</span> Approx. = 24,000</p>
<p class="">(About one-third in government sector)<a name="page509"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">509</span></span></p></li>
<li><p class=""><span class="italic">Trained optometrist:</span> Approx. = 54,000</p></li>
<li><p class=""><span class="italic">Paramedical ophthalmic assistant (PMOA)</span> = 40,000</p></li>
<li><p class=""><span class="italic">Need:</span> One ophthalmologist, one optometrist and One PMOA per 50,000 population</p></li>
<li><p class="">Cataract operation performed in the year 2021–22 = 6.19 million.</p></li>
<li><p class="">Donor eye collection in the year 2021−2022 = 45,294.</p></li>
</ul>
<p class="noindent"><span class="italic">Source</span>: NPCB VI, Ministry of Health and Family Welfare, Government of India (<a href="http://npcbvi.mohfw.gov.in" class="weblink">http://npcbvi.mohfw.gov.in</a>)</p>
</div>
<div class="section" id="ch26lev2sec9"><h2 class="title">Methods of Intervention (<a href="#ch26fig2" class="ulink-inter">Fig. 26.2</a>)</h2>
<div class="section" id="ch26lev3sec1"><h3 class="title">Community Sector</h3>
<ul style="list-style-type: bullet">
<li><p class="">ASHA workers</p></li>
<li><p class="">Primary school teachers</p></li>
<li><p class="">Eye care volunteers</p></li>
</ul>
<p class="noindent"><span class="italic">Service:</span> Eye care delivered in schools, homes and other community settings.</p>
<ul style="list-style-type: bullet">
<li><p class="">Detection of vision problem, squint in children</p></li>
<li><p class="">Presbyopia detection and counseling</p></li>
<li><p class="">To identify and guide them for Teleophthalmology, or to visit a primary or secondary center.</p></li>
<li><p class="">Eye health education.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec2"><h3 class="title">Peripheral (Primary) Sector</h3>
<ul style="list-style-type: bullet">
<li><p class="">Community health worker</p></li>
<li><p class="">Ophthalmic assistant at the primary health center (PHC), block primary health center (BPHC), and rural hospitals.</p></li>
</ul>
<div class="figure" id="ch26fig2" data-label="Fig. 26.2"><div class="title"><span class="item-label">Fig. 26.2</span> Community eye health care.</div><img alt="Fig. 26.2" src="/MediumImage/509-1.jpg"><div class="additional-markup"></div></div>
<p class="noindent"><a name="page510"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">510</span></span><span class="italic">Service:</span> Primary eye-health care</p>
<ul style="list-style-type: bullet">
<li><p class="">Treatment of common eye ailments, e.g., acute conjunctivitis, trachoma, superficial foreign body, etc.</p></li>
<li><p class="">Treatment of xerophthalmia</p></li>
<li><p class="">Vitamin A prophylaxis</p></li>
<li><p class="">Correction of refractive errors</p></li>
<li><p class="">Screening for cataract</p></li>
<li><p class="">Teleophthalmology services via vision center.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec3"><h3 class="title">Intermediate (Secondary) Sector</h3>
<ul style="list-style-type: bullet">
<li><p class="">Sub-divisional hospitals</p></li>
<li><p class="">District hospitals</p></li>
</ul>
<p class="noindent"><span class="italic">Service: Secondary eye-health care</span> (in addition to primary eye care).</p>
<ul style="list-style-type: bullet">
<li><p class="">Treatment of common blinding conditions, e.g., cataract, glaucoma, trichiasis, entropion, ocular trauma, etc.</p></li>
<li><p class="">Mobile ophthalmic units (MOU)</p></li>
<li><p class="">Eye camp via outreach program.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec4"><h3 class="title">Central (Tertiary) Sector</h3>
<ul style="list-style-type: bullet">
<li><p class="">Medical colleges and AIIMS in different states</p></li>
<li><p class="">State eye hospitals/institutes</p></li>
<li><p class="">Regional institutes of ophthalmology (RIOs)</p></li>
<li><p class="">National (Apex) eye institute</p></li>
</ul>
<p class="noindent"><span class="italic">Service: Tertiary eye-health care</span> (in addition to secondary eye care).</p>
<ul style="list-style-type: bullet">
<li><p class="">Sophisticated eye care, e.g., vitreoretinal surgeries, refractive surgeries, corneal grafting, and other complex surgeries</p></li>
<li><p class="">To provide eye bank services</p></li>
<li><p class="">To provide specialized training programs for all staff</p></li>
<li><p class="">To arrange continuing medical education program for the ophthalmologists</p></li>
<li><p class="">To undertake and promote research activities in ophthalmology.</p></li>
</ul>
<p class="indent"><span class="italic">Apex center (National Eye Institute)</span> is to function as a center of excellence to provide overall leadership, supervision, and guidance in technical matters in planning and implementation of the program.</p>
<p class="indent"><span class="italic">Dr Rajendra Prasad Center for Ophthalmic Sciences, AIIMS, New Delhi</span>, is identified for this purpose.</p>
</div>
</div>
<div class="section" id="ch26lev2sec10"><h2 class="title">Guidelines for Presbyopia under the NPCBVI</h2>
<p class="noindent">This is a new program initiated by the NPCBVI to combat presbyopia-related visual impairment.</p>
<p class="noindent"><span class="italic">Objective of the scheme:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">To further extend eye care services by distributing free spectacles for near work to old persons suffering from presbyopia.</p></li>
<li><p class="">To take care of elderly people in weaker section of the society.</p></li>
</ul>
<p class="indent"><span class="italic">Criterion for selection of beneficiary and distribution under the scheme:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Elderly people 45 years and above: Suffering from presbyopia are eligible for free spectacles on the prescription of government eye specialist.</p></li>
<li><p class="">These patients will be screened for the presbyopic correction in District Hospitals; Medical Colleges and RIOs; and any other Government Hospitals.</p></li>
<li><p class="">Preference will be given to the persons below poverty line.</p></li>
<li><p class="">The amount of assistance is up to ₹ 100 per presbyopic spectacles.</p></li>
</ul>
<p class="indent">The procurement of the spectacles will be made by the respective State/District Health Society by following proper procurement procedures similar to the purchase procedures being followed for purchase of spectacles for school children.</p>
</div>
<div class="section" id="ch26lev2sec11"><h2 class="title">Multipurpose District Mobile Ophthalmic Units</h2>
<p class="noindent">Multipurpose District Mobile Ophthalmic Units (MDMOU) are the new initiatives introduced under the 12th Five Year Plan with a view to further expand eye care coverage in <a name="page511"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">511</span></span>remote and underserved areas. Earlier, it was known as mobile ophthalmic unit (MOU).</p>
<p class="indent">It has been approved to develop 400 MDMOU in District Hospitals in a phased manner in the States/UTs during the 12th Five Year Plan. Preference will be given to remote/hilly areas including North-East States and underprivileged regions to expand eye care coverage.</p>
<p class="noindent"><span class="italic">The objectives of the scheme are:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">To operationalize MDMOU in district hospitals for improved access to eye care services.</p></li>
<li><p class="">To further expand eye care coverage.</p></li>
<li><p class="">To make eye care services available in remote and underprivileged areas of the country.</p></li>
</ul>
<p class="noindent"><span class="italic">The activities to be undertaken by MDMOU:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Screening via eye camps</p></li>
<li><p class="">School eye health screening</p></li>
<li><p class="">Transporting the patients from screening centers to the nearest district hospital/referral centre for further management</p></li>
<li><p class="">‘On the spot’ refraction and provision for glasses</p></li>
<li><p class="">Diagnosis of diseases like diabetic retinopathy, glaucoma, etc.</p></li>
<li><p class="">Display of IEC messages on the outer panels of mobile van.</p></li>
</ul>
<p class="noindent"><span class="italic">Composition of the MDMOU:</span></p>
<ol style="list-style-type: decimal">
<li><p class=""><span class="italic">Manpower:</span></p>
<ol style="list-style-type: lower-alpha">
<li><p class="">Paramedical ophthalmic assistant (PMOA)</p></li>
<li><p class="">Driver and cleaner/helper</p></li>
</ol></li>
<li><p class=""><span class="italic">Mobile van with following specifications:</span> It will be a 10-seater passenger carrier which includes driver and helper, a PMOA and six eye patients/school children.</p>
<p class="">The back of the van will be utilized for placing lens box, emergency tray and as store for spare essential material/items.</p></li>
<li><p class=""><span class="italic">Essential equipment in mobile van:</span></p>
<ol style="list-style-type: lower-alpha">
<li><p class="">Battery operated torch (2)</p></li>
<li><p class="">Illuminated vision testing drum</p></li>
<li><p class="">Illuminated handheld near vision testing drum</p></li>
<li><p class="">Snellen and near vision charts</p></li>
<li><p class="">Trial lens set with trial frames (2)</p></li>
<li><p class="">Streak retinoscope</p></li>
<li><p class="">Stationary (Glass prescription, OPD slips)</p></li>
<li><p class="">Direct ophthalmoscopes</p></li>
<li><p class="">Tonometers (Schiotz)</p></li>
<li><p class="">Binocular loupe</p></li>
<li><p class="">Epilation forceps</p></li>
<li><p class="">Lignocaine eye drops (4%)</p></li>
<li><p class="">Ishihara color vision chart</p></li>
<li><p class="">Mini storage cabinet with lock facility.</p></li>
</ol></li>
</ol>
<p class="noindent"><span class="italic">Administrative board of MDMOU:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">District Programme Manager (DPM) will be the officer-in-charge at district level</p></li>
<li><p class="">The medical officer in the PHC of the area will facilitate the eye camps</p></li>
<li><p class="">PHC or sub-center staffs and members of the village health committee</p></li>
<li><p class="">The post of driver and helper shall be filled up on contractual basis.</p></li>
</ul>
<div class="section" id="ch26lev3sec5"><h3 class="title">Specific National Programs</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Trachoma control program:</span> Early diagnosis and treatment can cure trachoma. This program launched in 1963, and has merged with NPCB in 1976.</p></li>
<li><p class=""><span class="italic">Vitamin A prophylaxis:</span> 200,000 IU of vitamin A as oil are given orally at 6 months interval between the age of 1 year and 5 years.</p></li>
<li><p class=""><span class="italic">School eye-health services:</span> It is estimated that 5–7% of children aged 5–14 years have problems with their eye-sight affecting their participation and learning at the school. This can be easily corrected by a pair of spectacles.</p>
<p class="">Other diseases, like vitamin A deficiency, squint, amblyopia, congenital anomalies, etc. can be detected earlier for further and better management.</p></li>
</ul>
<p class="noindent"><span class="italic">The school eye screening program seeks to:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Screen all children in the age group of 5–14 years for refractive errors (difficulty in clearly seeing distant or near objects).<a name="page512"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">512</span></span></p></li>
<li><p class="">Train teachers, preferably with science background, female teachers and those wearing spectacles for identifying children with eye problems.</p></li>
<li><p class="">Refer children with suspected refractive errors, to the Ophthalmic Assistant at the PHC for refraction.</p></li>
<li><p class="">Prescription of spectacles.</p></li>
<li><p class="">Provide children from poor families with free glasses. Annual target—15 lakh (2022–23).</p></li>
<li><p class="">Screening should be on an annual basis. In 2019–2020, more than 8.5 lakh free spectacles have been distributed among school children.</p></li>
<li><p class=""><span class="italic">Occupational eye-health services:</span> This is to prevent and treat eye hazards in industries. Education on the prevention of occupational eye hazards and use of protective devices in some occupations are important.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec6"><h3 class="title">District Blindness Control Society (DBCS)</h3>
<p class="noindent"><span class="italic">Features</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Autonomous society to implement NPCBVI</p></li>
<li><p class="">Representation consists of government, non-governmental organization, and private sectors</p></li>
<li><p class="">Decentralized planning, management, and monitoring</p></li>
<li><p class="">Direct funding from Government of India</p></li>
<li><p class="">Empowered to utilize and raise funds</p></li>
<li><p class="">Forum for community participation.</p></li>
</ul>
<p class="noindent"><span class="italic">Composition of DBCS</span></p>
<div class="informaltable"><div class="table-scroll"><table class="download">


<tbody>
<tr>
<td class="left"><p class="">Chairman</p></td>
<td class="left"><p class="">District Magistrate/District Collector/Deputy Commissioner</p></td>
</tr>
<tr>
<td class="left"><p class="">Vice-Chairman</p></td>
<td class="left"><p class="">Chief Medical Officer (CMO)</p></td>
</tr>
<tr>
<td class="left"><p class="">Technical Advisor</p></td>
<td class="left"><p class="">Head, Department of Ophthalmology of Medical College/District Ophthalmic Surgeon</p></td>
</tr>
<tr>
<td class="left"><p class="">Member Secretary</p></td>
<td class="left"><p class="">Deputy CMO or any Government Officer of equal rank or higher</p></td>
</tr>
<tr>
<td class="left"><p class="">Members</p></td>
<td class="left"><p class="">Representative of non-governmental organization (NGO), private sector and media.</p></td>
</tr>
</tbody>
</table></div></div>
<p class="noindent"><span class="italic">Functions of DBCS</span></p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Planning:</span> Preparation of the district micro-plan based on magnitude and distribution of blind persons and resources available for eye care.</p></li>
<li><p class=""><span class="italic">Implementation of program</span> through utilization of government facilities, involvement of NGOs, and community participation.</p></li>
<li><p class=""><span class="italic">Monitoring of program</span> activities and quality control.</p></li>
<li><p class=""><span class="italic">Financial and material management.</span></p></li>
<li><p class=""><span class="italic">Social mobilization and public awareness</span>.</p></li>
<li><p class=""><span class="italic">Orientation of various functionaries of health</span> and other sectors, formal and non-formal leaders.</p></li>
<li><p class=""><span class="italic">Procurement</span> of good quality refraction sets, drugs, consumable, cataract sets, etc. and maintenance of the equipment.</p></li>
<li><p class=""><span class="italic">Arrangement</span> for screening camps, intraocular lens (IOL), spectacles, generator sets, etc.</p></li>
<li><p class=""><span class="italic">Monitoring and financial assistance</span> to eye banks and eye donation centers.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec7"><h3 class="title">Manpower Development</h3>
<p class="noindent">Technical manpower development is an important priority for effective implementation of its services and time-bound targets achievement.</p>
<p class="noindent"><span class="italic">The priority training programs are:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Training of ophthalmic assistants</p></li>
<li><p class="">Training of mid-level ophthalmic personnels (MLOPs)</p></li>
<li><p class="">Orientation training to the medical officers of PHC, BPHC, and rural hospitals about the need of the NPCBVI<a name="page513"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">513</span></span></p></li>
<li><p class="">Refresher training course to the district ophthalmologists and ophthalmic assistants</p></li>
<li><p class="">Fellowship training to ophthalmologists and teachers of medical colleges under the prevention of blindness program.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec8"><h3 class="title">Information, Education, and Communication</h3>
<ul style="list-style-type: bullet">
<li><p class="">Information, education, and communication (IEC) is an important component of the program to increase community awareness on eye health.</p></li>
<li><p class="">NPCBVI utilizes the print, electronic, and social media to propagate IEC messages in public.</p></li>
<li><p class="">IEC strategy is developed in various states and subsequently followed at district level.</p></li>
<li><p class="">Local IEC activities include identification, motivation of potential beneficiaries, information through media, educating voluntary groups, teachers and other community-based volunteers including Accredited Social Health Activists (ASHA workers) identified under National Rural Health Mission (NRHM).</p></li>
<li><p class="">Interpersonal communication is the most effective method for motivation of target population.</p></li>
<li><p class="">Select group may be given one day orientation on blind registry, motivation and assistance for providing services for the affected population.</p></li>
<li><p class="">The orientation program is organized at PHC/CHC.</p></li>
<li><p class="">NPCBVI coordinates with other national programs like RBSK (Rashtriya Bal Swasthya Karyakram) and Ministry of Social Welfare and Empowerment.</p></li>
<li><p class="">People suffering from incurable blindness are provided rehabilitation from Ministry of Social Welfare and Empowerment for physical, vocational, and social therapy.</p></li>
</ul>
<p class="noindent">NPCBVI at the district level carries out screening in blind schools where children and adolescents are treated and referred for rehabilitation.</p>
<div class="sidebar">
<h2 class="title">Voluntary organizations</h2>
<p class="">Voluntary organizations or NGOs have played a vital role in the control of blindness in India. They are active in the field of educative, preventive, rehabilitative, and surgical services to control blindness for many years.</p>
<p class=""><span class="italic">Some of the active organizations:</span></p>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">Vision-2020 India with its members across the country</p></li>
<li><p class="">The Royal Commonwealth Society for the Blind (sight savers)</p></li>
<li><p class="">Lions International (sight first)</p></li>
<li><p class="">Rotary International and its branches</p></li>
<li><p class="">International Agency for Prevention of Blindness (IAPB)</p></li>
<li><p class="">Helen Keller International</p></li>
<li><p class="">ORBIS International and its branches</p></li>
<li><p class="">Helpage India, etc.</p></li>
<li><p class="">SightLife International</p></li>
</ul></p>
<p class=""><span class="italic">Other assistances</span></p>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">WHO assistance</p></li>
<li><p class="">Danish assistance</p></li>
<li><p class="">Indo-UK collaboration</p></li>
<li><p class="">World Bank assistance.</p></li>
</ul></p>
</div>
</div>
</div>
</div><div class="section" id="ch26lev1sec3"><h1 class="title">NUTRITIONAL BLINDNESS VITAMIN A DEFICIENCY</h1>
<p class="noindent">Vitamin A deficiency (VAD) along with protein−energy malnutrition (PEM) causes severe blinding corneal destruction.</p>
<p class="indent">Most of the time, VAD is precipitated by PEM and other diseases which precipitate malnutrition (e.g., measles, diarrhea, malaria or other acute illness in children).</p>
<p class="indent">Again malnutrition is caused by VAD. Together, this blindness is termed as <span class="italic">nutritional blindness</span>, though the main factor is <span class="italic">VAD</span>.</p>
<p class="indent"><span class="italic">Vitamin A deficiency is a systemic disease that affects cells and organs throughout the body.</span></p>
<p class="indent">The resultant changes in epithelial architecture are termed as <span class="italic">keratinizing metaplasia</span>.</p>
<p class="indent">The characteristic ocular manifestations of VAD ranging <span class="italic">from night blindness to corneal melting</span> are termed as <span class="italic">xerophthalmia (<a href="#ch26fig3" class="ulink-inter">Figs. 26.3</a> and <a href="#ch26fig4" class="ulink-inter">26.4</a>)</span>.<a name="page514"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">514</span></span></p>
<div class="figure" id="ch26fig3" data-label="Fig. 26.3"><div class="title"><span class="item-label">Fig. 26.3</span> Xerophthalmia.</div><img alt="Fig. 26.3" src="/MediumImage/514-1.jpg"><div class="additional-markup"></div></div>
<p class="indent">Approximately, one-fifth of preschool-age population of the world is estimated to be vitamin A deficient, with just less than 1% being night blind at any given time.</p>
<p class="indent">Vitamin A deficiency is largely limited to the first 4–6 years of life and is especially frequent among those 6 months to 3 years.</p>
<p class="indent">In India, about 20,000–25,000 preschool children suffer from VAD at any point of time.</p>
<div class="section" id="ch26lev2sec12"><h2 class="title">Major Signs and Symptoms of Xerophthalmia (WHO Classification)</h2>
<div class="sidebar">
<p class=""><div class="informaltable"><div class="table-scroll"><table class="download">



<tbody>
<tr>
<td class="left"><p class="">XN</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Night blindness</p></td>
</tr>
<tr>
<td class="left"><p class="">X1A</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Conjunctival xerosis</p></td>
</tr>
<tr>
<td class="left"><p class="">X1B</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Bitot's spot</p></td>
</tr>
<tr>
<td class="left"><p class="">X2</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Corneal xerosis</p></td>
</tr>
<tr>
<td class="left"><p class="">X3A</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Corneal ulceration/keratomalacia (&lt;1/3 corneal surface)</p></td>
</tr>
<tr>
<td class="left"><p class="">X3B</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Corneal ulceration/keratomalacia (&gt;1/3 corneal surface)</p></td>
</tr>
<tr>
<td class="left"><p class="">XS</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Corneal scar</p></td>
</tr>
<tr>
<td class="left"><p class="">XF</p></td>
<td class="left"><p class="">=</p></td>
<td class="left"><p class="">Xerophthalmic fundus</p></td>
</tr>
</tbody>
</table></div></div></p>
</div>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">XN (night blindness):</span> It is usually the <span class="italic">earliest manifestation</span> of VAD; sometimes termed as <span class="italic">chicken eyes</span> (chicken lack rods and are thus night blind).</p>
<p class="">Night blindness responds rapidly (within 24–48 hours) to vitamin A therapy.</p></li>
<li><p class=""><span class="italic">X1A and X1B (conjunctival xerosis and Bitot's spot):</span> The conjunctival epithelium in VAD, is transformed from normal columnar to stratified squamous with a resultant loss of goblet cells, formation of agranular cell layer and keratinization of the surface.</p>
<p class=""><span class="italic">Conjunctival xerosis (<a href="#ch26fig4" class="ulink-inter">Fig. 26.4A</a>)</span> first appears at the temporal side as an isolated oval or triangular patch, adjacent to the limbus in the interpalpebral fissure. It is almost always present in both eyes.</p>
<p class="">In some cases, keratin and saprophytic bacilli accumulate on the xerotic surface, giving it a foamy or cheesy appearance. These lesions are known as <span class="italic">Bitot's spots (<a href="#ch26fig4" class="ulink-inter">Fig. 26.4B</a>)</span>.</p>
<p class="">Isolated, usually temporal, patches of conjunctival xerosis or Bitot's spots are sometimes encountered in absence of active VAD <bold>(<a href="#ch26fig5" class="ulink-inter">Fig. 26.5</a>)</bold>.</p>
<p class="">In most instances, these patches represent persistent areas of squamous metaplasia induced during an earlier episode of VAD.</p>
<p class=""><div class="figure" id="ch26fig4" data-label="Figs. 26.4A and B"><div class="title"><span class="item-label">Figs. 26.4A and B</span> Bilateral conjunctival xerosis and Bitot's spot (X1A and 1B).</div><img alt="Figs. 26.4A and B" src="/MediumImage/514-2.jpg"><div class="additional-markup"></div></div></p>
<p class=""><a name="page515"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">515</span></span></p>
<p class=""><div class="figure" id="ch26fig5" data-label="Fig. 26.5"><div class="title"><span class="item-label">Fig. 26.5</span> Old Bitot's spot.</div><img alt="Fig. 26.5" src="/MediumImage/515-1.jpg"><div class="additional-markup"></div></div></p>
<p class="">The only certain means to distinguish an active lesion from an inactive lesion is to observe its response to vitamin A therapy. Active conjunctival xerosis and Bitot's spot begin to resolve within 2–5 days and mostly disappear by 2 weeks.</p></li>
<li><p class=""><span class="italic">X2 (corneal xerosis):</span> A hazy, lusterless dry appearance of the cornea, is first seen near the inferior limbus. Thick, keratinized plaques may form on the corneal surface and often more dense in the interpalpebral zone <bold>(<a href="#ch26fig6" class="ulink-inter">Fig. 26.6</a>)</bold>.</p>
<p class="">Corneal xerosis responds within 2–5 days to vitamin A therapy and it returns to normal appearance by 1–2 weeks.</p></li>
<li><p class=""><span class="italic">X3A and X3B (corneal ulceration/keratomalacia) (<a href="#ch26fig7" class="ulink-inter">Fig. 26.7</a>):</span> They indicate permanent destruction of a part, or all the corneal stroma, resulting in permanent structural alteration.</p>
<p class=""><div class="figure" id="ch26fig6" data-label="Fig. 26.6"><div class="title"><span class="item-label">Fig. 26.6</span> Corneal xerosis (X2).</div><img alt="Fig. 26.6" src="/MediumImage/515-2.jpg"><div class="additional-markup"></div></div></p>
<p class=""><div class="figure" id="ch26fig7" data-label="Fig. 26.7"><div class="title"><span class="item-label">Fig. 26.7</span> Keratomalacia (X3A) (arrows).</div><img alt="Fig. 26.7" src="/MediumImage/515-3.jpg"><div class="additional-markup"></div></div></p>
<p class="">These ulcers are classically oval or round punched out defects. The surrounding cornea is usually xerotic. The ulcer usually starts from slightly inferior and nasal aspects.</p>
<p class="">Perforation if occurs, becomes plugged with iris, thereby preserving the anterior chamber.</p>
<p class="">With therapy, superficial ulcers often heal surprisingly with little scarring, but deeper ulcers with perforation form adherent leukoma. Sometimes, a bigger perforation results with extrusion of intraocular contents leading to phthisis bulbi or pseudo-cornea formation leading to anterior staphyloma <bold>(<a href="#ch26fig8" class="ulink-inter">Fig. 26.8</a>)</bold>.</p>
<p class="">An emergency vitamin A therapy may still save the child's eyes to some extent.</p></li>
<li><p class=""><span class="italic">XS (xerophthalmic scar):</span> They are usually bilateral and indicate healed sequelae of prior corneal disease related to VAD <bold>(<a href="#ch26fig9" class="ulink-inter">Fig. 26.9</a>)</bold>.</p>
<p class="">They include <span class="italic">nebula, macula, leukoma, adherent leukoma, anterior staphyloma or phthisis bulbi (<a href="#ch26fig10" class="ulink-inter">Fig. 26.10</a>).</span></p></li>
<li><p class=""><span class="italic">XF [xerophthalmic (Uyemura's) fundus]:</span> Small white lesions on the retina, seen in some cases of VAD, are only of academic interest. They may be associated with constriction of the visual fields.<a name="page516"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">516</span></span></p></li>
</ul>
<div class="figure" id="ch26fig8" data-label="Fig. 26.8"><div class="title"><span class="item-label">Fig. 26.8</span> Keratomalacia (right eye) (X3B) and anterior staphyloma (left eye) (Xs).</div><img alt="Fig. 26.8" src="/MediumImage/516-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch26fig9" data-label="Fig. 26.9"><div class="title"><span class="item-label">Fig. 26.9</span> Bilateral xerophthalmic scar (XS).</div><img alt="Fig. 26.9" src="/MediumImage/516-2.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch26fig10" data-label="Fig. 26.10"><div class="title"><span class="item-label">Fig. 26.10</span> Bilateral old xerophthalmia—phthisis bulbi.</div><img alt="Fig. 26.10" src="/MediumImage/516-3.jpg"><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch26lev2sec13"><h2 class="title">Treatment</h2>
<p class="noindent"><span class="italic">Xerophthalmia is a medical emergency</span> as it carries a high risk of corneal destruction and blindness and/or sepsis and death.</p>
<p class="indent">Effective therapy is immediate administration of massive doses of vitamin A with concomitant treatment of underlying systemic illness and PEM, and prevention of any recurrence.</p>
<div class="section" id="ch26lev3sec9"><h3 class="title">Treatment Schedule for Xerophthalmia</h3>
<p class="noindent"><span class="italic">Vitamin A (WHO recommendation):</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Immediately upon diagnosis: 200,000 IU vitamin A orally</p></li>
<li><p class="">Next day: 200,000 IU vitamin A orally</p></li>
<li><p class="">Within 1–4 weeks: 200,000 IU orally</p></li>
<li><p class="">Children between 6 months and 11 months old, or less than 8 kg—half the above dose</p></li>
<li><p class="">Children less than 6 months old: One-quarter of the above dose.</p></li>
</ul>
<p class="indent"><span class="italic">Intramuscular injection of vitamin A (water-soluble)</span> 100,000 IU is usually given, when:</p>
<ul style="list-style-type: bullet">
<li><p class="">The children cannot swallow</p></li>
<li><p class="">In case of persistent vomiting</p></li>
<li><p class="">In severe malabsorption</p></li>
<li><p class="">Where the compliance is poor.</p>
<p class=""><span class="italic">Oral liquid, oil-based preparation of retinyl palmitate or retinyl acetate is preferred. It is safe, cheap, and highly effective even in presence of mild diarrhea (as it is also helpful for the intestinal epithelium).</span></p></li>
</ul>
<p class="noindent"><span class="italic">Medical status and diet:</span> Proper treatment includes rehydration, frequent feeding with easily digestible and protein-rich food, and general supportive care. Concurrent illness, e.g., respiratory infection, diarrhea, worm infestation, etc. should also be treated.</p>
<p class="noindent"><span class="italic">Eye care:</span> In case of corneal involvement:</p>
<ul style="list-style-type: bullet">
<li><p class=""><bold>Board-spectrum antibiotic ointment, e.g., chloramphenicol or gatifloxacin:</bold> 4 times daily</p></li>
<li><p class=""><bold>Atropine eye ointment:</bold> 2 times daily</p></li>
<li><p class="">If secondary infection is present—second antibiotic is added.</p></li>
<li><p class="">Artificial tears (PVA, CMC, or HPMC) eye drop—4 to 8 times daily.<a name="page517"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">517</span></span></p></li>
</ul>
<p class="noindent"><span class="italic">Preventing recurrence:</span> This is for the vulnerable children. By inexpensive, readily available vitamin A rich diet.</p>
<p class="indent">Periodic administration of a large dose of vitamin A at an interval of 4–6 months to ensure adequate vitamin A store in children <span class="italic">(see</span> later).</p>
</div>
</div>
<div class="section" id="ch26lev2sec14"><h2 class="title">Vitamin A Prophylaxis</h2>
<p class="noindent">Three main intervention strategies are as follows:</p>
<ol style="list-style-type: decimal">
<li><p class="">Increasing the dietary intake of foods rich in vitamin A and pro-vitamin A</p></li>
<li><p class="">Periodic administration of large doses of oral vitamin A</p></li>
<li><p class="">Administration of commonly consumable fortified food items (vitamin A fortification).</p></li>
</ol>
<div class="section" id="ch26lev3sec10"><h3 class="title">Increased Intake of Dietary Vitamin A</h3>
<p class="noindent">Dark-green leafy vegetables are usually the least expensive and most widely available source of vitamin A.</p>
<div class="sidebar">
<p class="">The daily requirement of vitamin A is obtained from a handful of fresh spinach (65 g) as from a small portion of liver (65 g), 4 medium-sized hen's eggs, 1.7 L of whole cow's milk or 6 kg of mutton.</p>
<p class="">The dark-green leafy vegetables should be boiled, shredded (mashed or sieved for the infants), and should be combined with a small amount of edible oil to improve vitamin A absorption.</p>
</div>
<p class="noindent"><span class="italic">Sources of vitamin A</span></p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Vegetable sources:</span> Dark-green leafy vegetables, spinach, carrot, tomato, pumpkin, etc.</p></li>
<li><p class=""><span class="italic">Animal sources:</span> Liver, meat, cod-liver oil, shark-liver oil, egg-yolk, etc.</p></li>
<li><p class=""><span class="italic">Fortified food items:</span> Vitamin A enriched commercially available food items.</p></li>
</ul>
<p class="noindent"><span class="italic">Daily requirements</span></p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">School children, adolescent and adults:</span> 2,250 IU (750 µg).</p></li>
<li><p class=""><span class="italic">Children (0–4 years):</span> 1,000–2,000 IU (300–400 µg).</p></li>
<li><p class=""><span class="italic">Pregnancy and lactation:</span> 3,000–3,500 IU (750 µg + 300 µg).</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec11"><h3 class="title">Periodic Supplementation</h3>
<p class="noindent"><span class="italic">Target group:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Infants 6–11 months of age (including HIV+): 100,000 IU vitamin A once.</p></li>
<li><p class="">Children 12–59 months of age (including HIV+): 200,000 IU vitamin A every 4–6 months</p></li>
</ul>
<p class="noindent"><span class="italic">Target group is determined by:</span> Where vitamin A deficiency is a public health problem—prevalence of night blindness is 1% or higher in children 24–59 months of age or where the prevalence of vitamin A deficiency (serum retinol 0.70 µmol/L or lower) is 20% or higher in infants and children 6–59 months of age.</p>
<p class="noindent">This prophylaxis may be for entire neighborhood <span class="italic">(mass prophylaxis)</span>, or for high-risk group <span class="italic">(selective prophylaxis)</span>.</p>
<p class="noindent"><span class="italic">The high-risk conditions are as follows:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Children with severe PEM</p></li>
<li><p class="">Children with measles</p></li>
<li><p class="">Children with diarrhea, lower respiratory tract infection, or other acute infection (e.g., malaria, chickenpox, etc.).</p></li>
</ul>
<p class="indent">They should receive a dose of 200,000 IU vitamin A orally at the time of diagnosis by the pediatrician.</p>
<p class="indent">Children below 1 year should receive half dose.</p>
</div>
<div class="section" id="ch26lev3sec12"><h3 class="title">Fortification of Dietary Items</h3>
<p class="noindent">Fortification, the addition of selected nutrients to common dietary items, is a successful means of protecting nutritional status of the children.</p>
<p class="indent">Dalda, milk, sugar, tea, cereal grains, bread, butter, margarine, etc., may be fortified with vitamin A.</p>
<p class="indent">The fortified foods should be inexpensive, stable and virtually undetectable in food vehicle selected, and they should be acceptable to the community.<a name="page518"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">518</span></span></p>
</div>
</div>
<div class="section" id="ch26lev2sec15"><h2 class="title">Ocular Findings in Other Vitamin Deficiencies</h2>
<div class="informaltable"><div class="table-scroll"><table class="download">


<tbody>
<tr>
<td class="left"><p class="">Vitamins</p></td>
<td class="left"><p class="">Ocular manifestations</p></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Vitamin B<sub>1</sub></bold> <bold>(Thiamine)</bold></p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Retrobulbar neuritis</p></li>
<li><p class="">Corneal hypoesthesia</p></li>
<li><p class="">Corneal and conjunctival degenerative changes</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Vitamin B<sub>2</sub></bold> <bold>(Riboflavin)</bold></p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Corneal vascularization</p></li>
<li><p class="">Punctate epithelial keratitis</p></li>
<li><p class="">Blepharoconjunctivitis</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Vitamin B<sub>12</sub></bold></p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Retrobulbar neuritis</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Vitamin C</bold></p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Delayed wound healing</p></li>
<li><p class="">Hemorrhage in the conjunctiva, retina or orbit</p></li>
<li><p class="">Keratoconjunctivitis</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Vitamin D</bold></p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Zonular cataract</p></li>
<li><p class="">Papilledema</p></li>
</ul></p></td>
</tr>
<tr>
<td class="left"><p class=""><bold>Vitamin K</bold></p></td>
<td class="left"><p class="">
<ul style="list-style-type: bullet">
<li><p class="">Hemorrhages in different ocular tissues</p></li>
</ul></p></td>
</tr>
</tbody>
</table></div></div>
</div>
</div><div class="section" id="ch26lev1sec4"><h1 class="title">VISION 2020: THE RIGHT TO SIGHT</h1>
<p class="noindent"><span class="italic">VISION 2020:</span> The Right to Sight is the global initiative for the elimination of avoidable blindness, a joint program of the World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB).</p>
<p class="noindent">It was launched in 1999.</p>
<div class="section" id="ch26lev2sec16"><h2 class="title">Aim</h2>
<p class="noindent">To intensify and accelerate present prevention of blindness activities so as to achieve the goal of eliminating avoidable blindness by the year 2020.</p>
<p class="indent">“World Sight Day is an annual day of awareness held on the second Thursday of October every year”.</p>
</div>
<div class="section" id="ch26lev2sec17"><h2 class="title">Present Position</h2>
<ul style="list-style-type: bullet">
<li><p class="">Up to 80% of global blindness is avoidable</p></li>
<li><p class="">180 million people worldwide are visually disabled</p></li>
<li><p class="">40–45 million people are totally blind</p></li>
<li><p class="">Sixty percent of blind population resides in sub-Saharan Africa, China, and India.</p></li>
</ul>
<p class="indent">Blindness will continue to increase by 2 million cases/year—unless more aggressive intervention is taken.</p>
<p class="noindent"><span class="italic">Action needed</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Disease control and eye care</p></li>
<li><p class="">Human resource development</p></li>
<li><p class="">Provision of appropriate technology and infrastructures.</p></li>
</ul>
<p class="indent">VISION 2020 will be implemented through 4 five-year plans. The first three have already expired in the year 2015. This last phase will be completed by the year 2020.</p>
<p class="indent"><span class="italic">Five conditions</span> have identified as immediate priorities within the framework of VISION 2020 program.</p>
<ol style="list-style-type: decimal">
<li><p class="">Cataract</p></li>
<li><p class="">Trachoma</p></li>
<li><p class="">Onchocerciasis</p></li>
<li><p class="">Childhood blindness</p></li>
<li><p class="">Refractive errors and low vision.</p></li>
</ol>
<p class="indent"><span class="italic">In India</span>, as there is no onchocerciasis, and trachoma is declining, <span class="italic">two</span> more diseases have been included recently in VISION-2020 India program.</p>
<p class="indent">These are <span class="italic">diabetic retinopathy</span> and <span class="italic">glaucoma</span>. They need special attention by all levels of eye healthcare personnel.</p>
</div>
<div class="section" id="ch26lev2sec18"><h2 class="title">Cataract</h2>
<p class="noindent"><span class="italic">Problem</span></p>
<ul style="list-style-type: bullet">
<li><p class="">20 million cataract backlog</p></li>
<li><p class="">8 million cataract operation/year globally</p></li>
<li><p class="">Worldwide problem.</p></li>
</ul>
<p class="noindent"><span class="italic">Action</span></p>
<ul style="list-style-type: bullet">
<li><p class="">To eliminate backlog by 2020</p></li>
<li><p class="">To provide good qualities of surgery:
<ul style="list-style-type: square">
<li><p class="">Accessible and affordable to all people</p></li>
<li><p class="">High success rate with IOL for all.</p></li>
</ul></p></li>
<li><p class="">Global cataract operation <span class="italic">target:</span>
<ul style="list-style-type: square">
<li><p class="">2000 <span class="italic">ad</span>—12 million</p></li>
<li><p class="">2010 <span class="italic">ad</span>—20 million</p></li>
<li><p class="">2020 <span class="italic">ad</span>—32 million.</p></li>
</ul></p></li>
</ul>
</div>
<div class="section" id="ch26lev2sec19"><h2 class="title">Trachoma</h2>
<p class="noindent"><span class="italic">Problem</span></p>
<ul style="list-style-type: bullet">
<li><p class="">146 million with active disease</p></li>
<li><p class="">10 million trichiasis</p></li>
<li><p class="">6 million blind</p></li>
<li><p class=""><a name="page519"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">519</span></span>Mostly in Africa, South-East Asia, Western Pacific, and Eastern Mediterranean.</p></li>
</ul>
<p class="noindent"><span class="italic">Action</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Implementation of SAFE in all endemic countries</p></li>
<li><p class="">5 million trichiasis surgery (by 2010)</p></li>
<li><p class="">Treatment of 60 million people (by 2010).</p></li>
<li><p class="">Total elimination by 2020.</p></li>
</ul>
<p class="noindent"><span class="italic">SAFE strategy for trachoma:</span></p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">S</span>urgery for trichiasis—the immediate precursor to corneal blindness</p></li>
<li><p class=""><span class="italic">A</span>ntibiotics—to treat active diseases—oral azithromycin or 1% tetracycline ointment</p></li>
<li><p class=""><span class="italic">F</span>acial cleanliness—to reduce person to person transmission</p></li>
<li><p class=""><span class="italic">E</span>nvironmental improvement—to affect the determinants of vulnerability.</p></li>
</ul>
</div>
<div class="section" id="ch26lev2sec20"><h2 class="title">Onchocerciasis</h2>
<p class="noindent"><span class="italic">Problem</span></p>
<ul style="list-style-type: bullet">
<li><p class="">17 million people infected</p></li>
<li><p class="">0.3–0.6 million blind</p></li>
<li><p class="">Mainly in African countries.</p></li>
</ul>
<p class="noindent"><span class="italic">Action</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Implementation of control program in endemic countries</p></li>
<li><p class="">Community-directive distribution of <span class="italic">ivermectin</span></p></li>
<li><p class="">Surveillance</p></li>
<li><p class="">Elimination by 2010 <span class="italic">ad</span></p></li>
<li><p class="">In 2015, Colombia, Ecuador, and Mexico were the three countries declared free of onchocerciasis.</p></li>
</ul>
<div class="sidebar">
<p class="">Dr Satoshi Ōmurao and Dr William C Campbell have been awarded Nobel Prize in Medicine, 2015 for the development of “Ivermectin”.</p>
</div>
</div>
<div class="section" id="ch26lev2sec21"><h2 class="title">Childhood Blindness</h2>
<p class="noindent"><span class="italic">Problem</span></p>
<ul style="list-style-type: bullet">
<li><p class="">1.5 million blind children in the world:
<ul style="list-style-type: square">
<li><p class="">Asia—1 million</p></li>
<li><p class="">Africa—0.3 million</p></li>
</ul></p></li>
<li><p class="">5 million visually disabled</p></li>
</ul>
<p class="noindent"><span class="italic">Action</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Promotion of primary eye care by:
<ul style="list-style-type: square">
<li><p class="">Elimination of vitamin A deficiency</p></li>
<li><p class="">Measles immunization</p></li>
<li><p class="">Prevention of newborn conjunctivitis.</p></li>
</ul></p></li>
<li><p class="">Development of pediatric eye care services:
<ul style="list-style-type: square">
<li><p class="">Surgery for squint, congenital cataract, congenital glaucoma, and retinopathy of prematurity.</p></li>
<li><p class="">Low visual aids.</p></li>
</ul></p></li>
</ul>
</div>
<div class="section" id="ch26lev2sec22"><h2 class="title">Refractive Errors and Low Vision</h2>
<p class="noindent"><span class="italic">Problem</span></p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Refractive errors</span>
<ul style="list-style-type: square">
<li><p class="">Magnitude not actually known</p></li>
<li><p class="">Varies from country to country.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Low vision</span>
<ul style="list-style-type: square">
<li><p class="">35 million in need of low visual aids</p></li>
<li><p class="">Will rapidly escalate because of aging and retinal problems.</p></li>
</ul></p></li>
</ul>
<p class="noindent"><span class="italic">Action</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Introduction of refractive services at the primary eye care level</p></li>
<li><p class="">Vision screening</p></li>
<li><p class="">Low cost production of glasses and low visual optical devices.</p></li>
</ul>
<div class="sidebar">
<p class=""><bold>Glaucoma</bold></p>
<p class="">Glaucoma has been declared to be the second most common cause of blindness in adult population in India. Glaucoma accounts for 8–13% of the blind and 12 million have estimated to have glaucoma. Studies have estimated that this number will increase to 31.6 million by 2020.</p>
<p class="indent">Primary angle-closure glaucoma (PACG) is more common than primary open angle glaucoma (POAG) (2–4 times) in Indian population. The high rate of blindness in Indian population is due to high proportion of undiagnosed glaucoma. Glaucoma was undetected in more than 90% of individuals in the population studied.</p>
<p class=""><bold>Diabetes</bold></p>
<p class="">India has the highest number of people with diabetes in the world with 31.7 million in 2000. This figure is estimated to rise to 79.4 million by 2030.</p>
<p class="indent">The prevalence of diabetic retinopathy in general population was 3.5%. The prevalence of diabetic retinopathy in the population with diabetes mellitus was 18.0%.<a name="page520"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">520</span></span></p>
</div>
</div>
<div class="section" id="ch26lev2sec23"><h2 class="title">Human Resource Development</h2>
<ul style="list-style-type: bullet">
<li><p class="">Number of ophthalmologists per million population has to be increased especially in Africa and Asia.</p></li>
<li><p class="">Equal distribution of eye care services for urban and rural population.</p></li>
<li><p class=""><span class="italic">Training of eye care supporting staffs:</span>
<ul style="list-style-type: square">
<li><p class="">Ophthalmic medical assistants</p></li>
<li><p class="">Ophthalmic nurses</p></li>
<li><p class="">Refractionists.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Management training:</span>
<ul style="list-style-type: square">
<li><p class="">For ophthalmologist</p></li>
<li><p class="">For paramedical staffs.</p></li>
</ul></p></li>
<li><p class="">Ophthalmic technician training.</p></li>
</ul>
</div>
<div class="section" id="ch26lev2sec24"><h2 class="title">Mission of VISION 2020 Program</h2>
<p class="noindent">To eliminate the main cause of blindness in order to give all people in the world, particularly the millions of needlessly blind, the right to sight <bold>(<a href="#ch26fig11" class="ulink-inter">Fig. 26.11</a>)</bold>.</p>
<div class="section" id="ch26lev3sec13"><h3 class="title">National Apex Center 1</h3>
<p class="noindent">Centers of excellence 20:</p>
<ul style="list-style-type: bullet">
<li><p class="">Profession leadership</p></li>
<li><p class="">Strategy development</p></li>
<li><p class="">Continued medical education (CME)</p></li>
<li><p class="">Laying of standards and quality assurance</p></li>
<li><p class="">Research.</p></li>
</ul>
<div class="figure" id="ch26fig11" data-label="Fig. 26.11"><div class="title"><span class="item-label">Fig. 26.11</span> The proposed structure for VISION 2020 program.</div><img alt="Fig. 26.11" src="/MediumImage/520-1.jpg"><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch26lev3sec14"><h3 class="title">Training Centers 200</h3>
<ul style="list-style-type: bullet">
<li><p class="">Tertiary eye care including retinal surgery, corneal transplantation, glaucoma surgery, etc.</p></li>
<li><p class="">Training and CME.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec15"><h3 class="title">Service Centers 2000</h3>
<ul style="list-style-type: bullet">
<li><p class="">Cataract surgery</p></li>
<li><p class="">Other common eye surgeries</p></li>
<li><p class="">Facilities for refraction and presbyopia correction</p></li>
<li><p class="">Referral services.</p></li>
</ul>
</div>
<div class="section" id="ch26lev3sec16"><h3 class="title">VISION Centers 20,000</h3>
<ul style="list-style-type: bullet">
<li><p class="">Refraction and prescription of glasses</p></li>
<li><p class="">Correction of presbyopia-related visual impairment.</p></li>
<li><p class="">Primary eye care</p></li>
<li><p class="">School eye screening program</p></li>
<li><p class="">Screening and referral services</p></li>
<li><p class="">Teleophthalmology services with the training centers.</p></li>
</ul>
</div>
</div>
</div><div class="section" id="ch26lev1sec5"><h1 class="title">VISION 2030 INSIGHT: ENDING AVOIDABLE SIGHT LOSS (IAPB)</h1>
<p class="noindent">There are now 1.1 billion people living with sight loss around the world because they don't have access to basic services. Without change, this will rise to 1.8 billion people by 2050.</p>
<p class="indent"><span class="italic">VISION 2020 was more than just a strategy and the impact is highly satisfactory with current data:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Global prevalence of blindness has dropped from 4.8% to 3.1% in 20 years.</p></li>
<li><p class=""><bold>Trachoma and Onchocerciasis,</bold> the two biggest infectious diseases which cause blindness, drastically lowered and could be eliminated within the next ten years.</p></li>
<li><p class="">90 million people around the world have had their vision impairment—treated or prevented.<a name="page521"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">521</span></span></p></li>
</ul>
<p class="noindent"><span class="italic">Goal of VISION 2030 Insight:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">No-one will experience unnecessary or preventable sight loss and everyone can achieve their full potential.</p></li>
<li><p class="">Eye care and rehabilitation services are accessible, inclusive and affordable to everyone, everywhere, whenever they are needed.</p></li>
</ul>
<p class="noindent"><span class="italic">Strategic plan:</span> To <bold>ELEVATE</bold> vision as a fundamental, economic, social and development issue, to <bold>INTEGRATE</bold> eye health in wider health care systems and to <bold>ACTIVATE</bold> consumer demand and market change.</p>
<p class="noindent"><bold>Targets:</bold> To address the two leading causes of blindness and vision impairment, <bold>cataract and refractive error</bold>. To address the huge unmet need in eye care, all countries have committed to: 40 percentage point increase in effective coverage of refractive and 30 percentage point increase in effective coverage of cataract surgery by 2030.</p>
<p class="noindent"><bold>These could be achieved by:</bold></p>
<ul style="list-style-type: bullet">
<li><p class="">Vision Screeners in School Program</p></li>
<li><p class="">Clear Vision: Workplace eye care</p></li>
<li><p class="">Pushing for inclusion in Universal Health Coverage</p></li>
<li><p class="">Delivering Integrated People-centered Eye Care (IPEC)</p></li>
<li><p class="">Training and Developing a Diverse and Resilient Workforce</p></li>
<li><p class="">Embracing technological solutions</p></li>
</ul>
<p class="noindent"><span class="italic">Source:</span> The International Agency for the Prevention of Blindness (IAPB)</p>
</div></div></div>